Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation

Journal of Infection

Volumn 72, Issue 5, 2016, Pages 597-607

  Blanco Lobo, P ^a   Cordero, E ^a   Martin Gandul C ^a   Gentil, M A ^a   Suarez Artacho G ^a   Sobrino, M ^a   Aznar, J ^a   Perez Romero P ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antibodies neutralizing epithelial cell infection; Cytomegalovirus; Immune monitoring; Preemptive therapy; Solid organ transplant patients

Indexed keywords

CD69 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; INCIDENCE; MALE; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ADVERSE EFFECTS; BLOOD; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; GRAFT RECIPIENT; IMMUNOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RISK ASSESSMENT; SERODIAGNOSIS; TRANSPLANTATION; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; EPITHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK ASSESSMENT; T-LYMPHOCYTES; TRANSPLANT RECIPIENTS; TRANSPLANTATION; YOUNG ADULT;

EID: 84960969033     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.02.008     Document Type: Article

References (29)

1. Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them?. Enferm Infecc Microbiol Clin 2010, 28:1-5.
2. Benmarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., Martín-Peña A., Sanchez B., Martin-Gandul C., et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011, 91:927-933.
3. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009, 9:1214-1222.
4. BenMarzouk-Hidalgo O.J., Cordero E., Gomez-Cia T., Sánchez M., González-Padilla J.D., Infante-Cossio P., et al. First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment. Antimicrob Agents Chemother 2011, 55:5949-5951.
5. Gimenez E., Blanco-Lobo P., Munoz-Cobo B., Solano C., Amat P., Pérez-Romero P., et al. The role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in the allogeneic stem cell transplantation setting. J General Virol 2015, 96:2822-2831.
6. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
7. Lilleri D., Kabanova A., Revello M.G., Percivalle E., Sarasini A., Genini E., et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pul128-130-131 complex during primary infection. PLoS One 2013, 8:e59863.
8. Bonaros N., Mayer B., Schachner T., Laufer G., Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008, 22:89-97.
9. Sinzger C., Grefte A., Plachter B., Gouw A.S., The T.H., Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J General Virol 1995, 76(Pt 4):741-750.
10. Genini E., Percivalle E., Sarasini A., Revello M.G., Baldanti F., Gerna G. Serum antibody response to the gH/gL/pul128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011, 52:113-118.
11. Wang D., Li F., Freed D.C., Finnefrock A.C., Tang A., Grimes S.N., et al. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 2011, 29:9075-9080.
12. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J General Virol 2008, 89:853-865.
13. Humar A., Lebranchu Y., Vincenti F., Blumberg E.A., Punch J.D., Limaye A.P., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10:1228-1237.
14. Torre-Cisneros J. Toward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the "individual pathogenic balance". Clin Infect Dis 2009, 49:1167-1168.
15. Manuel O., Husain S., Kumar D., Zayas C., Mawhorter S., Levi M.E., et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013, 56:817-824.
16. Lisboa L.F., Kumar D., Wilson L.E., Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93:195-200.
17. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
18. de la Torre-Cisneros J., Farinas M.C., Caston J.J., Aguado J.M., Cantisán S., Carratalá J., et al. Gesitra-seimc/reipi recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735-758.
19. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Danziger-Isakov L., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013, 96:333-360.
20. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79:10330-10338.
21. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
22. Eid A.J., Brown R.A., Arthurs S.K., Lahr B.D., Eckel-Passow J.E., Larson T.S., et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of cmv infection. Transpl Int 2010, 23:506-513.
23. La Rosa C., Limaye A.P., Krishnan A., Longmate J., Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late cmv disease. J Infect Dis 2007, 195:633-644.
24. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010, 10:157-161.
25. Humar A., Mazzulli T., Moussa G., Razonable R.R., Paya C.V., Pescovitz M.D., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005, 5:1065-1070.
26. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005, 102:18153-18158.
27. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78:10023-10033.
28. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. Characterization of the human cytomegalovirus gH/gL/ul128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008, 82:60-70.
29. Lilleri D., Kabanova A., Lanzavecchia A., Gerna G. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pul128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 2012, 32:1324-1331.